165 related articles for article (PubMed ID: 36700402)
1. Omalizumab alleviates pruritus in myeloproliferative neoplasms.
Ravn Landtblom A; Ungerstedt J; Hedlund A; Tobiasson M; Deneberg S; Jädersten M
Haematologica; 2023 Jul; 108(7):1968-1971. PubMed ID: 36700402
[No Abstract] [Full Text] [Related]
2. Danazol in refractory pruritus of myeloproliferative disorders.
Randi ML; Luzzatto G; Fabris F
Am J Hematol; 1997 Feb; 54(2):172-3. PubMed ID: 9034298
[No Abstract] [Full Text] [Related]
3. [Itching of the skin in myeloproliferative disease treated with cimetidine].
Berild D; Hasselbalch H
Ugeskr Laeger; 1985 Apr; 147(17):1403-4. PubMed ID: 4002413
[No Abstract] [Full Text] [Related]
4. Cholinergic pruritus responding to omalizumab.
Hasan SB; Ali FM; Ingram JR
Clin Exp Dermatol; 2020 Mar; 45(2):264-266. PubMed ID: 31323131
[No Abstract] [Full Text] [Related]
5. Clinical characteristics of aquagenic pruritus in patients with myeloproliferative neoplasms.
Le Gall-Ianotto C; Brenaut E; Gouillou M; Lacut K; Nowak E; Tempescul A; Berthou C; Ugo V; Carré JL; Misery L; Ianotto JC
Br J Dermatol; 2017 Jan; 176(1):255-258. PubMed ID: 27291777
[No Abstract] [Full Text] [Related]
6. Omalizumab for the management of refractory aquagenic pruritus.
Koumaki D; Gregoriou S; Katoulis A; Evangelou G
J Eur Acad Dermatol Venereol; 2023 Nov; 37(11):e1316-e1317. PubMed ID: 37415343
[No Abstract] [Full Text] [Related]
7. Reply to 'Omalizumab for the management of refractory aquagenic pruritus'.
Martora F; Napolitano M; De Lucia M; D'Agostino M; Patruno C
J Eur Acad Dermatol Venereol; 2024 May; 38(5):e380-e381. PubMed ID: 37909098
[No Abstract] [Full Text] [Related]
8. Cutaneous manifestations of JAK2+ myeloproliferative neoplasms.
Kentley J; Theodoulou A; Wijesuriya N; Ekeowa-Anderson A
Clin Exp Dermatol; 2018 Jul; 43(5):615-616. PubMed ID: 29756220
[No Abstract] [Full Text] [Related]
9. Cimetidine for the treatment of pruritus.
Hess CE
N Engl J Med; 1979 Feb; 300(7):370. PubMed ID: 759904
[No Abstract] [Full Text] [Related]
10. Aquagenic pruritus successfully treated with omalizumab.
Murphy B; Duffin M; Tolland J
Clin Exp Dermatol; 2018 Oct; 43(7):858-859. PubMed ID: 29450908
[No Abstract] [Full Text] [Related]
11. Danazol relieves refractory pruritus associated with myeloproliferative disorders and other diseases.
Kolodny L; Horstman LL; Sevin BU; Brown H; Ahn YS
Am J Hematol; 1996 Feb; 51(2):112-6. PubMed ID: 8579050
[TBL] [Abstract][Full Text] [Related]
12. Aquagenic pruritus and the JAK2 V617F mutation.
Langabeer SE
Clin Exp Dermatol; 2019 Apr; 44(3):e33. PubMed ID: 30578575
[No Abstract] [Full Text] [Related]
13. Relief of itch associated with myeloproliferative disease by alpha-interferon.
Flecknoe-Brown S
Aust N Z J Med; 1991 Feb; 21(1):81. PubMed ID: 2036085
[No Abstract] [Full Text] [Related]
14. Regional itching and hyperhidrosis in myeloproliferative disorder with fibrosis: studies on a muscarinic cholinergic receptor M3.
Setoyama A; Yamaguchi T; Yoshioka M; Nishio D; Nakamura M
Eur J Dermatol; 2014; 24(4):487-8. PubMed ID: 24921967
[No Abstract] [Full Text] [Related]
15. Clinical response to omalizumab in patients with hereditary α-tryptasemia.
Mendoza Alvarez LB; Barker R; Nelson C; DiMaggio T; Stone KD; Milner JD; Rosenthal JA; Petroni DH; Glover SC; Lyons JJ
Ann Allergy Asthma Immunol; 2020 Jan; 124(1):99-100.e1. PubMed ID: 31605754
[No Abstract] [Full Text] [Related]
16. IgE blockade in the management of eosinophil-associated recalcitrant pruritus due to medical tumor therapy.
Gutzmer R; Sibaud V; Hassel JC
Ann Oncol; 2021 Jun; 32(6):696-697. PubMed ID: 33882330
[No Abstract] [Full Text] [Related]
17. Special issues in myeloproliferative neoplasms.
Barbui T; Finazzi G
Curr Hematol Malig Rep; 2011 Mar; 6(1):28-35. PubMed ID: 21181458
[TBL] [Abstract][Full Text] [Related]
18. Mast cells as a therapeutic target in myeloproliferative neoplasms.
Toledo MAS; Chatain N; Zenke M; Koschmieder S
Trends Mol Med; 2022 Nov; 28(11):902-905. PubMed ID: 36064534
[TBL] [Abstract][Full Text] [Related]
19. Differences between aquagenic and non-aquagenic pruritus in myeloproliferative neoplasms: An observational study of 500 patients.
Le Gall-Ianotto C; Ficheux AS; Lippert E; Herbreteau L; Rio L; Pan-Petesch B; Misery L; Ianotto JC
J Eur Acad Dermatol Venereol; 2023 Jun; 37(6):1175-1183. PubMed ID: 36808754
[TBL] [Abstract][Full Text] [Related]
20. Patient-reported outcomes in urticarial vasculitis treated with omalizumab: case report.
Cherrez-Ojeda I; Vanegas E; Felix M; Mata VL; Cherrez A
BMC Dermatol; 2018 Oct; 18(1):8. PubMed ID: 30359231
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
